Biocon Biologics Gets UK Nod To Market Denosumab Biosimilars Vevzuo, Evfraxy

Biocon Biologics Ltd., a subsidiary of Biocon Ltd., has received marketing authorisation from the UK’s Medicines and Healthcare products Regulatory Agency for its Denosumab biosimilars, Vevzuo and Evfraxy. These drugs are used to prevent bone complications in patients with advanced cancer and giant cell tumours of the bone.

The two biosimilars will be marketed by Biosimilar Collaborations Ireland Ltd. This approval follows a similar nod from the European Commission, based on a positive opinion from the European Medicines Agency’s drug committee in April.